Anavex Life Sciences Files Q3 2024 10-Q

TL;DR

Anavex Life Sciences filed its Q3 2024 10-Q. Financials and operations updated.

AI Summary

Anavex Life Sciences Corp. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results for the third quarter and the first nine months of fiscal year 2024. Key financial data and operational updates are detailed within the filing.

Why It Matters

This filing provides investors with the latest financial performance and operational status of Anavex Life Sciences, crucial for understanding the company's trajectory in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — As a life sciences company, Anavex is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.

Key Numbers

• 2024-06-30 — Period End Date (End of the third fiscal quarter of 2024.)
• 2024-08-06 — Filing Date (Date the 10-Q was officially filed with the SEC.)

Key Players & Entities

• ANAVEX LIFE SCIENCES CORP. (company) — Filer
• 0001314052 (company) — Central Index Key
• 20240630 (date) — Period of Report
• 20240806 (date) — Filed as of Date
• 630 5TH AVENUE (address) — Business Address

FAQ

Key Financial Figures

• $0.001 — ich Registered Common Stock Par Value $0.001 AVXL NASDAQ Stock Market LLC Indi
• $150.0 million — ary 3, 2023, the Company entered into a $150.0 million purchase agreement (the "2023 Purchase

Filing Documents

• e5842_10-q.htm (10-Q) — 707KB
• e5842_ex31-1.htm (EX-31.1) — 9KB
• e5842_ex31-2.htm (EX-31.2) — 9KB
• e5842_ex32-1.htm (EX-32.1) — 7KB
• image_001.jpg (GRAPHIC) — 27KB
• image_002.jpg (GRAPHIC) — 28KB
• 0001731122-24-001207.txt ( ) — 3547KB
• avxl-20240630.xsd (EX-101.SCH) — 27KB
• avxl-20240630_cal.xml (EX-101.CAL) — 29KB
• avxl-20240630_def.xml (EX-101.DEF) — 91KB
• avxl-20240630_lab.xml (EX-101.LAB) — 250KB
• avxl-20240630_pre.xml (EX-101.PRE) — 199KB
• e5842_10-q_htm.xml (XML) — 443KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 4

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 19

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS. 38

CONTROLS AND PROCEDURES

ITEM 4. CONTROLS AND PROCEDURES 38

– OTHER INFORMATION

PART II – OTHER INFORMATION 39

LEGAL PROCEEDINGS

ITEM 1. LEGAL PROCEEDINGS 39

RISK FACTORS

ITEM 1A. RISK FACTORS 39

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 39

DEFAULTS UPON SENIOR SECURITIES

ITEM 3. DEFAULTS UPON SENIOR SECURITIES 39

MINE SAFETY DISCLOSURES

ITEM 4. MINE SAFETY DISCLOSURES 39

OTHER INFORMATION

ITEM 5. OTHER INFORMATION 39

EXHIBITS

ITEM 6. EXHIBITS 40

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS 4 Anavex Life Sciences Corp. Condensed Consolidated Interim Financial Statements June 30, 2024 (Unaudited) 5 Anavex Life Sciences Corp. Condensed Consolidated Interim Balance Sheets (in thousands, except share and per share amounts) June 30, September 30, 2024 2023 (Unaudited) Assets Current Cash and cash equivalents $ 138,756 $ 151,024 Incentive and tax receivables 1,720 2,709 Prepaid expenses and other current assets 1,059 653 Total Assets $ 141,535 $ 154,386 Liabilities and Stockholders' Equity Current Liabilities Accounts payable $ 3,503 $ 4,322 Accrued liabilities - Note 4 7,334 7,295 Deferred grant income - Note 3 917 917 Total Liabilities $ 11,754 $ 12,534 Commitments and Contingencies - Note 6 — — Capital stock Authorized: 10,000,000 preferred stock, par value $ 0.001 per share — — 200,000,000 common stock, par value $ 0.001 per share Issued and outstanding: 84,795,517 common shares (September 30, 2023 - 82,066,511 ) 85 82 Additional paid-in capital 454,236 434,839 Share proceeds receivable ( 89 ) — Accumulated deficit ( 324,451 ) ( 293,069 ) Total Stockholders' Equity $ 129,781 $ 141,852 Total Liabilities and Stockholders' Equity $ 141,535 $ 154,386 See Accompanying Notes to Condensed Consolidated Interim Financial Statements 6 Anavex Life Sciences Corp. Condensed Consolidated Interim Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) Three months ended June 30, Nine months ended June 30, 2024 2023 2024 2023 Operating expenses General and administrative $ 2,859 $ 3,248 $ 8,258 $ 9,447 Research and development 11,870 10,283 30,283 33,657 Total operating expenses 14,729 13,531 38,541 43,104 Operating loss ( 14,729 ) ( 13,531 ) ( 38,541 ) ( 43,104 ) Other income (expense) Grant income — — — 25 Research and development i

Business

Business Anavex Life Sciences Corp. ("Anavex" or the "Company") is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system ("CNS") diseases with high unmet need. Anavex analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The Company's lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 ("MECP2"). Note 2 Basis of Presentation Basis of Presentation These accompanying unaudited condensed consolidated interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim reporting. Accordingly, certain information and note disclosures normally included in the annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the disclosures are adequate to make the information presented not misleading. These accompanying unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated balance sheet as of September 30, 2023 was derived from the audited annual financial statements but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed consolidated interim financial statements should b

View Full Filing

View this 10-Q filing on SEC EDGAR